The article discusses the role of angiogenesis in cancer, emphasizing its importance in tumor growth and metastasis. Angiogenesis, the formation of new blood vessels, is regulated by both activator and inhibitor molecules. Over a dozen different proteins have been identified as angiogenic activators, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and transforming growth factor (TGF)-α. These factors are crucial for supplying nutrients and oxygen to tumors and removing waste products. However, up-regulation of angiogenic factors alone is not sufficient for angiogenesis; negative regulators or inhibitors of vessel growth must also be down-regulated. Endogenous inhibitors of angiogenesis include angiostatin, endostatin, interferon, and thrombospondin. These inhibitors induce apoptosis in endothelial cells and tumor cells, inhibit migration, and stabilize newly formed blood vessels. Studies have shown that the expression of angiogenic factors reflects the aggressiveness of tumor cells and has predictive value in identifying high-risk patients with poor prognosis. The article also reviews the clinical application of antiangiogenic treatments, which aim to reduce the supply of nutrients and oxygen to tumors. Despite initial optimism, long-term survival benefits have not been documented. However, when combined with chemotherapy or radiation therapy, antiangiogenic drugs have shown modest positive outcomes. The normalization of tumor vasculature is a promising strategy, but more research is needed to fully understand its potential. Overall, the article highlights the complex interplay between angiogenesis and cancer, emphasizing the need for comprehensive treatment strategies that integrate antiangiogenic agents with conventional cytoreductive treatments.The article discusses the role of angiogenesis in cancer, emphasizing its importance in tumor growth and metastasis. Angiogenesis, the formation of new blood vessels, is regulated by both activator and inhibitor molecules. Over a dozen different proteins have been identified as angiogenic activators, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and transforming growth factor (TGF)-α. These factors are crucial for supplying nutrients and oxygen to tumors and removing waste products. However, up-regulation of angiogenic factors alone is not sufficient for angiogenesis; negative regulators or inhibitors of vessel growth must also be down-regulated. Endogenous inhibitors of angiogenesis include angiostatin, endostatin, interferon, and thrombospondin. These inhibitors induce apoptosis in endothelial cells and tumor cells, inhibit migration, and stabilize newly formed blood vessels. Studies have shown that the expression of angiogenic factors reflects the aggressiveness of tumor cells and has predictive value in identifying high-risk patients with poor prognosis. The article also reviews the clinical application of antiangiogenic treatments, which aim to reduce the supply of nutrients and oxygen to tumors. Despite initial optimism, long-term survival benefits have not been documented. However, when combined with chemotherapy or radiation therapy, antiangiogenic drugs have shown modest positive outcomes. The normalization of tumor vasculature is a promising strategy, but more research is needed to fully understand its potential. Overall, the article highlights the complex interplay between angiogenesis and cancer, emphasizing the need for comprehensive treatment strategies that integrate antiangiogenic agents with conventional cytoreductive treatments.